Interleukin-15 in kidney disease and therapeutics.

Journal

Current opinion in nephrology and hypertension

ISSN: 1473-6543

Titre abrégé: Curr Opin Nephrol Hypertens

Pays: England

ID NLM: 9303753

Informations de publication

Date de publication:
27 Dec 2023

Historique:

medline: 2 1 2024

pubmed: 2 1 2024

entrez: 2 1 2024

Statut: aheadofprint

Résumé

Interleukin 15 (IL-15) is a member of the IL-2 family of common gamma chain receptor cytokines with well described anti-inflammatory, pro-survival and pro-proliferative signaling properties. The cytoprotective role of IL-15 in the kidney is now coming into focus with recent reports of its beneficial actions in various forms of kidney disease. This review will summarize what is currently known about IL-15 signaling in the kidney and highlight recent evidence of its beneficial effects on kidney physiology. IL-15 and its heterotrimeric receptor are expressed throughout the kidney. Like all IL-2 family cytokines, IL-15 can activate signaling through the Janus Kinase (JAK)/Signal transducer of activated T-cells (STAT), phosphoinositol-3 kinase (PI-3K)/AKT and mitogen activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) pathways and recent evidence suggests that STAT5B is an essential transcriptional mediator of prosurvival signaling in glomerular visceral epithelial cells (i.e. podocytes). IL-15 has also been shown to suppress pro-apoptotic signaling in models of acute kidney injury and pro-fibrotic signaling in models of chronic kidney disease. The cytoprotective properties of IL-15 suggest that it may have potential as a nonimmunosuppresive therapeutic for kidney disease. A novel class of IL-15 immunotherapies has emerged for the treatment cancer and some have demonstrated efficacy in clinical trials. These well tolerated IL-15 agonists could possibly be repurposed for the treatment of kidney disease and warrant further exploration.

Identifiants

DOI: 10.1097/MNH.0000000000000964 PMID: 38164877

pubmed: 38164877

doi: 10.1097/MNH.0000000000000964

pii: 00041552-990000000-00131

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Informations de copyright

Références

Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood 2001; 97:14–32.

Burton JD, Bamford RN, Peters C, et al. A lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc Natl Acad Sci USA 1994; 91:4935–4939.

Grabstein KH, Eisenman J, Shanebeck K, et al. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 1994; 264:965–968.

Nicola NA, Hilton DJ. General classes and functions of four-helix bundle cytokines. Adv Protein Chem 1998; 52:1–65.

Budagian V, Bulanova E, Paus R, Bulfone-Paus S. IL-15/IL-15 receptor biology: a guided tour through an expanding universe. Cytokine Growth Factor Rev 2006; 17:259–280.

Giri JG, Ahdieh M, Eisenman J, et al. Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J 1994; 13:2822–2830.

Giri JG, Anderson DM, Kumaki S, et al. IL-15, a novel T cell growth factor that shares activities and receptor components with IL-2. J Leukoc Biol 1995; 57:763–766.

Cosman D, Kumaki S, Ahdieh M, et al. Interleukin 15 and its receptor. Ciba Found Symp 1995; 195:221–229.

Tejman-Yarden N, Zlotnik M, Lewis E, et al. Renal cells express a functional interleukin-15 receptor. Nephrol Dial Transplant 2005; 20:516–523.

Giron-Michel J, Azzi S, Khawam K, et al. Interleukin-15 plays a central role in human kidney physiology and cancer through the gammac signaling pathway. PLoS One 2012; 7:e31624.

Azzi S, Gallerne C, Romei C, et al. Human renal normal, tumoral, and cancer stem cells express membrane-bound interleukin-15 isoforms displaying different functions. Neoplasia 2015; 17:509–517.

Yuan H, Meng X, Guo W, et al. Transmembrane-bound IL-15-promoted epithelial-mesenchymal transition in renal cancer cells requires the Src-dependent Akt/GSK-3beta/beta-catenin pathway. Neoplasia 2015; 17:410–420.

Giron-Michel J, Azzi S, Ferrini S, et al. Interleukin-15 is a major regulator of the cell-microenvironment interactions in human renal homeostasis. Cytokine Growth Factor Rev 2013; 24:13–22.

Khawam K, Giron-Michel J, Gu Y, et al. Human renal cancer cells express a novel membrane-bound interleukin-15 that induces, in response to the soluble interleukin-15 receptor alpha chain, epithelial-to-mesenchymal transition. Cancer Res 2009; 69:1561–1569.

Pavlakis M, Strehlau J, Lipman M, et al. Intragraft IL-15 transcripts are increased in human renal allograft rejection. Transplantation 1996; 62:543–545.

Strehlau J, Pavlakis M, Lipman M, et al. The intragraft gene activation of markers reflecting T-cell-activation and -cytotoxicity analyzed by quantitative RT-PCR in renal transplantation. Clin Nephrol 1996; 46:30–33.

Strehlau J, Pavlakis M, Lipman M, et al. Quantitative detection of immune activation transcripts as a diagnostic tool in kidney transplantation. Proc Natl Acad Sci USA 1997; 94:695–700.

Tilly G, Doan-Ngoc TM, Yap M, et al. IL-15 harnesses pro-inflammatory function of TEMRA CD8 in kidney-transplant recipients. Front Immunol 2017; 8:778.

Weiler M, Rogashev B, Einbinder T, et al. Interleukin-15, a leukocyte activator and growth factor, is produced by cortical tubular epithelial cells. J Am Soc Nephrol 1998; 9:1194–1201.

Weiler M, Kachko L, Chaimovitz C, et al. CD40 ligation enhances IL-15 production by tubular epithelial cells. J Am Soc Nephrol 2001; 12:80–87.

Eini H, Tejman-Yarden N, Lewis EC, et al. Association between renal injury and reduced interleukin-15 and interleukin-15 receptor levels in acute kidney injury. J Interferon Cytokine Res 2010; 30:1–8.

Shinozaki M, Hirahashi J, Lebedeva T, et al. IL-15, a survival factor for kidney epithelial cells, counteracts apoptosis and inflammation during nephritis. J Clin Invest 2002; 109:951–960.

Nagai H, Takizawa T, Nishiyori T, Koda A. Experimental glomerulonephritis in mice as a model for immunopharmacological studies. Jpn J Pharmacol 1982; 32:1117–1124.

Nagai H, Yamada H, Nishigaki T, et al. The susceptibility of experimental glomerulonephritis in six different strains of mice. J Pharmacobiodyn 1985; 8:586–589.

Mooslechner AA, Schuller M, Artinger K, et al. Low-dose rIL-15 protects from nephrotoxic serum nephritis via CD8(+) T cells. Cells 2022; 11:3656.

Luque Y, Cathelin D, Vandermeersch S, et al. Glomerular common gamma chain confers B- and T-cell-independent protection against glomerulonephritis. Kidney Int 2017; 91:1146–1158.

Nahas AME. Masugi nephritis: a model for all seasons. S. Karger AG; 1993.

Zhang T, Liu X, Zhao Y, et al. Excessive IL-15 promotes cytotoxic CD4 + CD28- T cell-mediated renal injury in lupus nephritis. Immun Ageing 2022; 19:50.

Devocelle A, Lecru L, Francois H, et al. Inhibition of TGF-beta1 signaling by IL-15: a novel role for IL-15 in the control of renal epithelial-mesenchymal transition: IL-15 counteracts TGF-beta1-induced EMT in renal fibrosis. Int J Cell Biol 2019; 2019:9151394.

Devocelle A, Lecru L, Ferlicot S, et al. IL-15 prevents renal fibrosis by inhibiting collagen synthesis: a new pathway in chronic kidney disease? Int J Mol Sci 2021; 22:11698.

Chevalier RL, Forbes MS, Thornhill BA. Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. Kidney Int 2009; 75:1145–1152.

Yang HC, Zuo Y, Fogo AB. Models of chronic kidney disease. Drug Discov Today Dis Models 2010; 7:13–19.

Liu X, Liu Z, Wang C, et al. Kidney tubular epithelial cells control interstitial fibroblast fate by releasing TNFAIP8-encapsulated exosomes. Cell Death Dis 2023; 14:672.

Aïssata Niasse KL, Olivia L, Chloé S, et al. Protective role of podocytic IL-15 /STAT5 pathway in experimental focal and segmental glomerulosclerosis. BioRvix 2022.

Grahammer F, Schell C, Huber TB. The podocyte slit diaphragm--from a thin grey line to a complex signalling hub. Nat Rev Nephrol 2013; 9:587–598.

Gbadegesin RA, Hall G, Adeyemo A, et al. Mutations in the gene that encodes the F-actin binding protein anillin cause FSGS. J Am Soc Nephrol 2014; 25:1991–2002.

Hall G, Lane BM, Khan K, et al. The human FSGS-causing ANLN R431C mutation induces dysregulated PI3K/AKT/mTOR/Rac1 signaling in podocytes. J Am Soc Nephrol 2018; 29:2110–2122.

Li L, Tang W, Zhang Y, et al. Targeting tissue-resident memory CD8(+) T cells in the kidney is a potential therapeutic strategy to ameliorate podocyte injury and glomerulosclerosis. Mol Ther 2022; 30:2746–2759.

Floege J, Hackmann B, Kliem V, et al. Age-related glomerulosclerosis and interstitial fibrosis in Milan normotensive rats: a podocyte disease. Kidney Int 1997; 51:230–243.

Famulski KS, Halloran PF. Molecular events in kidney ageing. Curr Opin Nephrol Hypertens 2005; 14:243–248.

Kaverina N, Schweickart RA, Chan GC, et al. Inhibiting NLRP3 signaling in aging podocytes improves their life- and health-span. Aging (Albany NY) 2023; 15:6658–6689.

Zhang L, Zhou F, Yu X, et al. C/EBPalpha deficiency in podocytes aggravates podocyte senescence and kidney injury in aging mice. Cell Death Dis 2019; 10:684.

Fang Y, Chen B, Liu Z, et al. Age-related GSK3beta overexpression drives podocyte senescence and glomerular aging. J Clin Invest 2021; 22:11698.

Kreidberg JA, Schumacher VA. GSK3beta and the aging kidney. J Clin Invest 2022; 132:e155885.

Pippin JW, Kaverina N, Wang Y, et al. Upregulated PD-1 signaling antagonizes glomerular health in aged kidneys and disease. J Clin Invest 2022; 132:e156250.

Yu SM, He JC. Aged glomeruli: a link between PD-1 and podocytes. J Clin Invest 2022; 132:e162330.

Shankland SJ, Wang Y, Shaw AS, et al. Podocyte aging: why and how getting old matters. J Am Soc Nephrol 2021; 32:2697–2713.

Camici M, Carpi A, Cini G, et al. Podocyte dysfunction in aging--related glomerulosclerosis. Front Biosci (Schol Ed) 2011; 3:995–1006.

Rossiello F, Jurk D, Passos JF, d’Adda di Fagagna F. Telomere dysfunction in ageing and age-related diseases. Nat Cell Biol 2022; 24:135–147.

Blackburn EH, Gall JG. A tandemly repeated sequence at the termini of the extrachromosomal ribosomal RNA genes in Tetrahymena. J Mol Biol 1978; 120:33–53.

Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 1965; 37:614–636.

Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res 1961; 25:585–621.

Taheri M, Ghafouri-Fard S, Najafi S, et al. Hormonal regulation of telomerase activity and hTERT expression in steroid-regulated tissues and cancer. Cancer Cell Int 2022; 22:258.

Bodnar AG, Ouellette M, Frolkis M, et al. Extension of life-span by introduction of telomerase into normal human cells. Science 1998; 279:349–352.

Yang J, Chang E, Cherry AM, et al. Human endothelial cell life extension by telomerase expression. J Biol Chem 1999; 274:26141–26148.

Avilion AA, Piatyszek MA, Gupta J, et al. Human telomerase RNA and telomerase activity in immortal cell lines and tumor tissues. Cancer Res 1996; 56:645–650.

Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997; 33:787–791.

Li Y, Zhi W, Wareski P, Weng NP. IL-15 activates telomerase and minimizes telomere loss and may preserve the replicative life span of memory CD8+ T cells in vitro. J Immunol 2005; 174:4019–4024.

Watkinson F, Nayar SK, Rani A, et al. IL-15 upregulates telomerase expression and potently increases proliferative capacity of NK, NKT-like, and CD8 T cells. Front Immunol 2020; 11:594620.

Isvoranu G, Surcel M, Munteanu AN, et al. Therapeutic potential of interleukin-15 in cancer (review). Exp Ther Med 2021; 22:675.

Xue D, Hsu E, Fu YX, Peng H. Next-generation cytokines for cancer immunotherapy. Antib Ther 2021; 4:123–133.

Conlon KC, Lugli E, Welles HC, et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J Clin Oncol 2015; 33:74–82.

Kim PS, Kwilas AR, Xu W, et al. IL-15 superagonist/IL-15RalphaSushi-Fc fusion complex (IL-15SA/IL-15RalphaSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent antitumor activity against murine breast and colon carcinomas. Oncotarget 2016; 7:16130–16145.

Zhu X, Marcus WD, Xu W, et al. Novel human interleukin-15 agonists. J Immunol 2009; 183:3598–3607.

Liu B, Kong L, Han K, et al. A novel fusion of ALT-803 (interleukin (IL)-15 superagonist) with an antibody demonstrates antigen-specific antitumor responses. J Biol Chem 2016; 291:23869–23881.

Zhou Y, Husman T, Cen X, et al. Interleukin 15 in cell-based cancer immunotherapy. Int J Mol Sci 2022; 23:7311.

Stoklasek TA, Schluns KS, Lefrancois L. Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo. J Immunol 2006; 177:6072–6080.

Cai M, Huang X, Huang X, et al. Research progress of interleukin-15 in cancer immunotherapy. Front Pharmacol 2023; 14:1184703.

Bernstein ZJ, Spangler JB. Insights into the anticancer mechanisms of interleukin-15 from engineered cytokine therapies. J Clin Invest 2021; 131:e152857.

Knudson KM, Hodge JW, Schlom J, Gameiro SR. Rationale for IL-15 superagonists in cancer immunotherapy. Expert Opin Biol Ther 2020; 20:705–709.

Kennedy MK, Glaccum M, Brown SN, et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med 2000; 191:771–780.

Lodolce JP, Boone DL, Chai S, et al. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 1998; 9:669–676.

Evans R, Fuller JA, Christianson G, et al. IL-15 mediates antitumor effects after cyclophosphamide injection of tumor-bearing mice and enhances adoptive immunotherapy: the potential role of NK cell subpopulations. Cell Immunol 1997; 179:66–73.

Armitage RJ, Macduff BM, Eisenman J, et al. IL-15 has stimulatory activity for the induction of B cell proliferation and differentiation. J Immunol 1995; 154:483–490.

Edelbaum D, Mohamadzadeh M, Bergstresser PR, et al. Interleukin (IL)-15 promotes the growth of murine epidermal gamma delta T cells by a mechanism involving the beta- and gamma c-chains of the IL-2 receptor. J Invest Dermatol 1995; 105:837–843.

Gordy LE, Bezbradica JS, Flyak AI, et al. IL-15 regulates homeostasis and terminal maturation of NKT cells. J Immunol 2011; 187:6335–6345.